Sports technology companies report Revenue and losses while building commercial traction. HITIQ Limited (ASX:HIQ) released its Appendix 4E and Annual Report for the year ended 30 June 2026, signed on 28 August 2026.

Company overview

HITIQ Limited (ASX:HIQ) develops concussion management technology, including the PROTEQT platform and instrumented mouthguards that measure head impacts. Its products serve sport, research, defence and insurance markets.

FY26 results

Revenue from ordinary activities fell 21.0% to A$1,592,466, and the loss after tax attributable to owners was A$6,101,158, down 15.4% from A$7,212,305. No dividends were paid or declared. The financial statements were audited with an unmodified opinion.

Commercialisation progress

The Board’s letter describes FY26 as a defining year in which HITIQ accelerated commercialisation of its concussion management platform and widened its presence across retail, research, defence and insurance markets. It continued the rollout of PROTEQT while extending the technology into institutional and consumer channels.

A key milestone was work with the Australian Sports Commission through The Park program, where the instrumented mouthguard technology was used in a blinded pilot project across Australian combat sports to compare objective head impact data with athlete-reported symptoms.

Where HITIQ sells and who it serves

The Board’s letter says HITIQ widened its presence across retail, research, defence and insurance markets, and extended its technology into new institutional and consumer channels while rolling out PROTEQT. These are different customers with different sales cycles, from consumer retail to defence and insurance procurement.

The Australian Sports Commission pilot used HITIQ’s instrumented mouthguard in a blinded study across combat sports, comparing objective head impact data with athlete-reported symptoms.

Reading the financial statements

With revenue of A$1.59 million and a loss of A$6.10 million, expenses far exceeded income, which is typical for an early-commercial technology company funded by investors. A 15.4% reduction in the loss suggests lower costs relative to the prior year, though the release extract does not detail cost lines.

The Appendix 4E states no dividends were paid, recommended or declared in either year, and that the accounts carry an unmodified audit opinion.

Sector backdrop

Concussion management is an area of growing attention for sporting bodies, insurers and defence organisations, and companies in the field often depend on pilots, institutional procurement and regulatory acceptance.

Early-stage technology firms usually report losses while revenue builds, and fund operations through Equity raisings.

Companies in this stage typically disclose cash and funding in their quarterly Cash Flow reports, and investors compare cash balances against annual cash use to estimate how long operations can be funded. The annual report’s notes on Going Concern and subsequent events contain that information, and shareholders may wish to review those sections alongside the Board’s letter.

The Board’s letter is forward-looking in tone about commercialisation, but the Appendix 4E itself reports only historical results, so statements about future adoption are management expectations and not outcomes.

Head impact sensors and concussion management products serve a growing interest in athlete welfare, with regulators, insurers and sporting bodies considering objective measures. Adoption typically requires validation studies and endorsements.

Investors in such companies usually track revenue growth, contract wins and cash runway.

Risks shareholders should weigh

Revenue declined 21.0% while the company remains loss-making at about A$6.1 million for the year. The annual report may include going concern or funding commentary that readers should review.

Sales cycles with institutions can be long, and pilot programs do not always convert into commercial contracts.

The release does not provide forecasts.

Falling revenue combined with ongoing losses means the company depends on additional funding, and the full annual report should be reviewed for cash balance and going concern disclosures.

Converting pilot programs and institutional interest into Recurring Revenue is not assured.

What’s next

HITIQ will continue the rollout of PROTEQT and pursue institutional channels. Shareholders may wish to watch for contract announcements and funding updates.